Literature DB >> 11304758

Differential distribution of cAMP-specific phosphodiesterase 7A mRNA in rat brain and peripheral organs.

X Miró1, S Pérez-Torres, J M Palacios, P Puigdomènech, G Mengod.   

Abstract

We investigated the regional distribution and cellular localization of mRNA coding for the cAMP-specific phosphodiesterase 7A (PDE7A) in rat brain and several peripheral organs by in situ hybridization histochemistry. The regional expression of two splice variants, PDE7A1 and PDE7A2, was examined by RT-PCR using RNA extracted from several brain regions. PDE7A mRNA was found to be widely distributed in rat brain in both neuronal and nonneuronal cell populations. The highest levels of hybridization were observed in the olfactory bulb, olfactory tubercle, hippocampus, cerebellum, medial habenula nucleus, pineal gland, area postrema, and choroid plexus. Positive hybridization signals were also detected in other areas, such as raphe nuclei, temporal and entorhinal cortex, pontine nuclei, and some cranial nerve motor nuclei. Both mRNA splice forms were differentially distributed in several areas of the brain with the striatum expressing only PDE7A1 and the olfactory bulb and spinal cord expressing PDE7A2 exclusively. In peripheral organs the highest levels of PDE7A hybridization were seen in kidney medulla, although testis, liver, adrenal glands, thymus, and spleen also presented high hybridization signal. These results are consistent with PDE7A being involved in the regulation of cAMP signaling in many brain functions. The consistent colocalization with PDE4 mRNAs suggests that PDE7A could have an effect on memory, depression, and emesis. The results offer clear anatomical and functional systems in which to investigate future specific PDE7 inhibitors. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11304758     DOI: 10.1002/syn.1043

Source DB:  PubMed          Journal:  Synapse        ISSN: 0887-4476            Impact factor:   2.562


  18 in total

1.  PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis.

Authors:  L Mestre; M Redondo; F J Carrillo-Salinas; J A Morales-García; S Alonso-Gil; A Pérez-Castillo; C Gil; A Martínez; C Guaza
Journal:  Br J Pharmacol       Date:  2015-07-14       Impact factor: 8.739

Review 2.  Can Cyclic Nucleotide Phosphodiesterase Inhibitors Be Drugs for Parkinson's Disease?

Authors:  Dominic Ngima Nthenge-Ngumbau; Kochupurackal P Mohanakumar
Journal:  Mol Neurobiol       Date:  2017-01-06       Impact factor: 5.590

3.  A genome-wide scan for common variants affecting the rate of age-related cognitive decline.

Authors:  Philip L De Jager; Joshua M Shulman; Lori B Chibnik; Brendan T Keenan; Towfique Raj; Robert S Wilson; Lei Yu; Sue E Leurgans; Dong Tran; Cristin Aubin; Christopher D Anderson; Alessandro Biffi; Jason J Corneveaux; Matthew J Huentelman; Jonathan Rosand; Mark J Daly; Amanda J Myers; Eric M Reiman; David A Bennett; Denis A Evans
Journal:  Neurobiol Aging       Date:  2011-11-04       Impact factor: 4.673

4.  Identification in silico and experimental validation of novel phosphodiesterase 7 inhibitors with efficacy in experimental autoimmune encephalomyelitis mice.

Authors:  Miriam Redondo; Valle Palomo; José Brea; Daniel I Pérez; Rocío Martín-Álvarez; Concepción Pérez; Nuria Paúl-Fernández; Santiago Conde; María Isabel Cadavid; María Isabel Loza; Guadalupe Mengod; Ana Martínez; Carmen Gil; Nuria E Campillo
Journal:  ACS Chem Neurosci       Date:  2012-08-08       Impact factor: 4.418

5.  Inhibition of endogenous phosphodiesterase 7 promotes oligodendrocyte precursor differentiation and survival.

Authors:  E M Medina-Rodríguez; F J Arenzana; J Pastor; M Redondo; V Palomo; R García de Sola; C Gil; A Martínez; A Bribián; F de Castro
Journal:  Cell Mol Life Sci       Date:  2013-05-10       Impact factor: 9.261

6.  Increased particulate phosphodiesterase 4 in the prefrontal cortex supports 5-HT4 receptor-induced improvement of object recognition memory in the rat.

Authors:  Guénaëlle Levallet; Maïté Hotte; Michel Boulouard; François Dauphin
Journal:  Psychopharmacology (Berl)       Date:  2008-08-15       Impact factor: 4.530

Review 7.  Phosphodiesterases as therapeutic targets for Alzheimer's disease.

Authors:  Ana García-Osta; Mar Cuadrado-Tejedor; Carolina García-Barroso; Julen Oyarzábal; Rafael Franco
Journal:  ACS Chem Neurosci       Date:  2012-10-01       Impact factor: 4.418

Review 8.  Emerging targets for addiction neuropharmacology: From mechanisms to therapeutics.

Authors:  Massimo Ubaldi; Nazzareno Cannella; Roberto Ciccocioppo
Journal:  Prog Brain Res       Date:  2015-11-26       Impact factor: 2.453

9.  Selective inhibition of phosphodiesterase 7 enzymes reduces motivation for nicotine use through modulation of mesolimbic dopaminergic transmission.

Authors:  Roberto Ciccocioppo; Giordano de Guglielmo; Hongwu Li; Miriam Melis; Lucia Caffino; Quienwei Shen; Ana Domi; Fabio Fumagalli; Gregory A Demopulos; George A Gaitanaris
Journal:  J Neurosci       Date:  2021-06-01       Impact factor: 6.167

Review 10.  Selective phosphodiesterase inhibitors: a promising target for cognition enhancement.

Authors:  Olga A H Reneerkens; Kris Rutten; Harry W M Steinbusch; Arjan Blokland; Jos Prickaerts
Journal:  Psychopharmacology (Berl)       Date:  2008-08-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.